Immunotherapy combo may boost liver cancer ablation success
NCT ID NCT06045975
First seen Apr 26, 2026 · Last updated May 10, 2026 · Updated 2 times
Summary
This study tests whether giving two immunotherapy drugs (durvalumab and tremelimumab) before a standard liver cancer ablation procedure, followed by durvalumab alone for 11 months, can reduce the chance of cancer coming back. It involves 30 adults with early-stage liver cancer who are eligible for ablation. The main goal is to see how long the cancer stays away from the treated area.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HCC - HEPATOCELLULAR CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Hospitl Avicenne
Bobigny, 93000, France
Conditions
Explore the condition pages connected to this study.